Silvan Tuerkcan
Stock Analyst at JMP Securities
(3.20)
# 1,219
Out of 4,413 analysts
99
Total ratings
40%
Success rate
2.59%
Average return
Main Sectors:
Top Industries:
16 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACRV Acrivon Therapeutics | Maintains: Market Outperform | $14 → $17 | $8.23 | +106.56% | 3 | Apr 25, 2024 | |
| BNTC Benitec Biopharma | Maintains: Market Outperform | $10 → $16 | $7.90 | +102.53% | 7 | Apr 22, 2024 | |
| NTBL Notable Labs | Reiterates: Market Outperform | $9 | $0.91 | +884.68% | 3 | Apr 15, 2024 | |
| EXEL Exelixis | Reiterates: Market Outperform | $27 | $21.93 | +23.15% | 11 | Apr 10, 2024 | |
| MGNX MacroGenics | Reiterates: Market Outperform | n/a | $15.55 | - | 9 | Apr 4, 2024 | |
| VOR Vor Biopharma | Reiterates: Market Outperform | $12 | $1.77 | +577.97% | 8 | Mar 22, 2024 | |
| TSHA Taysha Gene Therapies | Reiterates: Market Outperform | $5 | $2.42 | +106.61% | 9 | Mar 20, 2024 | |
| TERN Terns Pharmaceuticals | Maintains: Outperform | $17 → $15 | $5.08 | +195.28% | 7 | Mar 18, 2024 | |
| ELEV Elevation Oncology | Reiterates: Market Outperform | $7 | $4.00 | +75.00% | 2 | Mar 7, 2024 | |
| MNDY monday.com | Maintains: Buy | $240 → $280 | $189.95 | +47.41% | 3 | Mar 5, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Market Outperform | $74 → $80 | $53.81 | +48.67% | 10 | Dec 11, 2023 | |
| CLLS Cellectis | Reiterates: Market Outperform | $6 | $2.54 | +136.59% | 5 | Nov 1, 2023 | |
| GBIO Generation Bio Co. | Downgrades: Market Perform | n/a | $2.91 | - | 7 | Oct 23, 2023 | |
| RLAY Relay Therapeutics | Maintains: Market Outperform | $28 → $24 | $6.66 | +260.36% | 6 | May 5, 2023 | |
| TWO Two Harbors Investment | Maintains: Market Outperform | $18 → $18 | $12.73 | +41.40% | 1 | Jan 26, 2023 | |
| NTLA Intellia Therapeutics | Downgrades: Market Perform | n/a | $22.50 | - | 8 | Jan 19, 2023 |
Acrivon Therapeutics
Apr 25, 2024
Maintains: Market Outperform
Price Target: $14 → $17
Current: $8.23
Upside: +106.56%
Benitec Biopharma
Apr 22, 2024
Maintains: Market Outperform
Price Target: $10 → $16
Current: $7.90
Upside: +102.53%
Notable Labs
Apr 15, 2024
Reiterates: Market Outperform
Price Target: $9
Current: $0.91
Upside: +884.68%
Exelixis
Apr 10, 2024
Reiterates: Market Outperform
Price Target: $27
Current: $21.93
Upside: +23.15%
MacroGenics
Apr 4, 2024
Reiterates: Market Outperform
Price Target: n/a
Current: $15.55
Upside: -
Vor Biopharma
Mar 22, 2024
Reiterates: Market Outperform
Price Target: $12
Current: $1.77
Upside: +577.97%
Taysha Gene Therapies
Mar 20, 2024
Reiterates: Market Outperform
Price Target: $5
Current: $2.42
Upside: +106.61%
Terns Pharmaceuticals
Mar 18, 2024
Maintains: Outperform
Price Target: $17 → $15
Current: $5.08
Upside: +195.28%
Elevation Oncology
Mar 7, 2024
Reiterates: Market Outperform
Price Target: $7
Current: $4.00
Upside: +75.00%
monday.com
Mar 5, 2024
Maintains: Buy
Price Target: $240 → $280
Current: $189.95
Upside: +47.41%
CRISPR Therapeutics AG
Dec 11, 2023
Maintains: Market Outperform
Price Target: $74 → $80
Current: $53.81
Upside: +48.67%
Cellectis
Nov 1, 2023
Reiterates: Market Outperform
Price Target: $6
Current: $2.54
Upside: +136.59%
Generation Bio Co.
Oct 23, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $2.91
Upside: -
Relay Therapeutics
May 5, 2023
Maintains: Market Outperform
Price Target: $28 → $24
Current: $6.66
Upside: +260.36%
Two Harbors Investment
Jan 26, 2023
Maintains: Market Outperform
Price Target: $18 → $18
Current: $12.73
Upside: +41.40%
Intellia Therapeutics
Jan 19, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $22.50
Upside: -